Literature DB >> 7028635

A combination of amoxicillin and clavulanic acid in the treatment of respiratory tract infections caused by amoxicillin-resistant haemophilus influenzae.

H Beeuwkes, V H Rutgers.   

Abstract

This study was undertaken to evaluate the efficacy of a fixed combination of amoxicillin and clavulanic acid in 33 patients with chronic or recurrent respiratory tract infections (R.T.I.), mainly bronchitis. In two patients bronchopneumonia was diagnosed, and in one cystic fibrosis. The patients were treated with 750 mg of the drug combination (500 mg amoxicillin/250 mg clavulanic acid) t. i. d. for seven or ten days. Good clinical success was obtained in 17 patients and a clear improvement in another eight. The most frequently isolated micro-organism was Haemophilus influenzae; of the 22 strains isolated, 20 were resistant to 2 mg/l amoxicillin but sensitive to the combination of 2 mg/l amoxicillin and 1 mg/l clavulanic acid. Side-effects were reported in nine patients; two patients discontinued treatment for this reason. Amoxicillin/clavulanic acid is a useful therapeutic addition to the existing forms of treatment for amoxicillin-resistant respiratory tract infections.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7028635     DOI: 10.1007/bf01640725

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  15 in total

1.  The in vitro activity of mezlocillin when combined with cefoxitin or clavulanic acid.

Authors:  R Wise; A P Gillett; J M Andrews
Journal:  J Antimicrob Chemother       Date:  1979-05       Impact factor: 5.790

2.  Clavulanic acid: a beta-lactamase-inhiting beta-lactam from Streptomyces clavuligerus.

Authors:  C Reading; M Cole
Journal:  Antimicrob Agents Chemother       Date:  1977-05       Impact factor: 5.191

3.  Effect of clavulanic acid on the minimum inhibitory concentration of benzylpenicillin, ampicillin, carbenicillin, or cephalothin against clinical isolates resistant to beta-lactam antibiotics.

Authors:  L Dumon; P Adriaens; J Anné; H Eyssen
Journal:  Antimicrob Agents Chemother       Date:  1979-02       Impact factor: 5.191

4.  Combined activitiy of clavulanic acid and ticarcillin against ticarcillin-resistant, gram-negative bacilli.

Authors:  J W Paisley; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1978-08       Impact factor: 5.191

5.  Clavulanic acid and susceptibility of Bacteroides fragilis to penicillin.

Authors:  R Wise
Journal:  Lancet       Date:  1977-07-16       Impact factor: 79.321

6.  Bronchopulmonary infection due to beta-lactamase-producing Branhamella catarrhalis treated with amoxycillin/clavulanic-acid.

Authors:  G Ninane; J Joly; M Kraytman; P Piot
Journal:  Lancet       Date:  1978-07-29       Impact factor: 79.321

7.  Factors contributing to resistance to beta-lactam antibiotics in Bacteroides fragilis.

Authors:  B Olsson; K Dornbusch; C E Nord
Journal:  Antimicrob Agents Chemother       Date:  1979-02       Impact factor: 5.191

8.  Inhibition of beta-lactamase in Neisseria gonorrhoeae by sodium clavulanate.

Authors:  J M Miller; C N Baker; C Thornsberry
Journal:  Antimicrob Agents Chemother       Date:  1978-11       Impact factor: 5.191

9.  Clavulanic acid, a novel inhibitor of beta-lactamases.

Authors:  H C Neu; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1978-11       Impact factor: 5.191

10.  Effect of clavulanic Acid on anaerobic bacteria resistant to Beta-lactam antibiotics.

Authors:  J Wüst; T D Wilkins
Journal:  Antimicrob Agents Chemother       Date:  1978-01       Impact factor: 5.191

View more
  6 in total

1.  Single-dose pharmacokinetics of intravenous clavulanic acid with amoxicillin in pediatric patients.

Authors:  U B Schaad; P A Casey; D L Cooper
Journal:  Antimicrob Agents Chemother       Date:  1983-02       Impact factor: 5.191

Review 2.  Amoxicillin/clavulanic acid. An update of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  P A Todd; P Benfield
Journal:  Drugs       Date:  1990-02       Impact factor: 9.546

3.  Amoxicillin combined with clavulanic acid for the treatment of soft tissue infections in children.

Authors:  G R Fleisher; C M Wilmott; J M Campos
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

4.  Amoxicillin-clavulanic acid in the treatment of lower respiratory tract infections caused by beta-lactamase-positive Haemophilus influenzae and Branhamella catarrhalis.

Authors:  R J Wallace; L C Steele; D L Brooks; J I Luman; R W Wilson; J W McLarty
Journal:  Antimicrob Agents Chemother       Date:  1985-06       Impact factor: 5.191

5.  In vitro activity of amoxicillin plus clavulanic acid against Haemophilus influenzae and Branhamella catarrhalis.

Authors:  B O Liljequist; L Gezelius
Journal:  Eur J Clin Microbiol       Date:  1986-12       Impact factor: 3.267

6.  Cholestatic hepatitis due to antibacterial combination of amoxicillin and clavulanic acid (augmentin)

Authors:  B H Stricker; J W Van den Broek; J Keuning; W Eberhardt; H G Houben; M Johnson; A P Blok
Journal:  Dig Dis Sci       Date:  1989-10       Impact factor: 3.199

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.